CL2021003142A1 - Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb. - Google Patents

Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb.

Info

Publication number
CL2021003142A1
CL2021003142A1 CL2021003142A CL2021003142A CL2021003142A1 CL 2021003142 A1 CL2021003142 A1 CL 2021003142A1 CL 2021003142 A CL2021003142 A CL 2021003142A CL 2021003142 A CL2021003142 A CL 2021003142A CL 2021003142 A1 CL2021003142 A1 CL 2021003142A1
Authority
CL
Chile
Prior art keywords
disorders
compounds
small molecule
molecule inhibitors
inducing kinase
Prior art date
Application number
CL2021003142A
Other languages
English (en)
Inventor
Alec D Lebsack
Kevin D Kreutter
Wenying Chai
Paul J Krawczuk
J Kent Barbay
Wendy Eccles
Michael D Hack
Aaron T Herrmann
William M Jones
Daniel J Pippel
Alexander R Rovira
Ronald L Wolin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2021003142A1 publication Critical patent/CL2021003142A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente invención se relaciona con compuestos que inhiben el NIK y composiciones farmacéuticas que comprenden tales compuestos y métodos para el uso de estos. Se prevé que estos compuestos y composiciones farmacéuticas son útiles para prevenir o tratar enfermedades tales como cáncer (tal como neoplasias de células B que incluyen leucemias, linfomas y mieloma), trastornos inflamatorios, trastornos autoinmunes, trastornos inmunodermatológicos tales como pustulosis palmoplantar e hidradenitis supurativa, y trastornos metabólicos tales como obesidad y diabetes.
CL2021003142A 2019-05-31 2021-11-25 Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb. CL2021003142A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30

Publications (1)

Publication Number Publication Date
CL2021003142A1 true CL2021003142A1 (es) 2022-08-19

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003142A CL2021003142A1 (es) 2019-05-31 2021-11-25 Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb.

Country Status (22)

Country Link
US (2) US11254673B2 (es)
EP (1) EP3976597A1 (es)
JP (1) JP2022534302A (es)
KR (1) KR20220027871A (es)
CN (1) CN114222737A (es)
AU (1) AU2020282005A1 (es)
BR (1) BR112021023796A2 (es)
CA (1) CA3143350A1 (es)
CL (1) CL2021003142A1 (es)
CO (1) CO2021017838A2 (es)
CR (1) CR20210587A (es)
DO (1) DOP2021000244A (es)
EC (1) ECSP21093623A (es)
IL (1) IL288387A (es)
JO (1) JOP20210318A1 (es)
MA (1) MA56038A (es)
MX (1) MX2021014679A (es)
PE (1) PE20220768A1 (es)
SG (1) SG11202112994WA (es)
TW (1) TW202110842A (es)
UY (1) UY38721A (es)
WO (1) WO2020239999A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
UY38721A (es) * 2019-05-31 2020-11-30 Janssen Pharmaceutica Nv INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
WO2023217879A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
WO2023217906A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
MX2007000791A (es) * 2004-08-03 2007-03-23 Wyeth Corp Indazoles utiles en el tratamiento de enfermedades cardiovasculares.
US7453156B2 (en) 2004-11-12 2008-11-18 Chippac, Inc. Wire bond interconnection
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CA2827161A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
EP2814830A1 (en) * 2012-02-17 2014-12-24 F.Hoffmann-La Roche Ag Tricyclic compounds and methods of use therefor
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CA2921881A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
JP2016533385A (ja) * 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
BR112017008045A2 (pt) 2014-10-23 2017-12-19 Janssen Pharmaceutica Nv compostos como inibidores de nik
WO2016062791A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
CN107074881B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的噻吩并嘧啶衍生物
WO2016062790A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
JP2018510140A (ja) 2015-02-25 2018-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
US11001569B2 (en) 2016-01-22 2021-05-11 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
AU2017209935B2 (en) 2016-01-22 2021-04-01 Janssen Pharmaceutica Nv New substituted cyanoindoline derivatives as NIK inhibitors
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
EP3504206B1 (en) 2016-08-24 2022-03-23 F. Hoffmann-La Roche AG 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN109863142B (zh) * 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
EP3649127B1 (en) 2017-07-06 2021-09-08 Janssen Pharmaceutica NV Substituted azaindoline derivatives as nik inhibitors
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
UY38721A (es) * 2019-05-31 2020-11-30 Janssen Pharmaceutica Nv INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها
EP3976179A1 (en) 2019-05-31 2022-04-06 Chiesi Farmaceutici S.p.A. Amino quinazoline derivatives as p2x3 inhibitors
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators

Also Published As

Publication number Publication date
TW202110842A (zh) 2021-03-16
UY38721A (es) 2020-11-30
US11827634B2 (en) 2023-11-28
MA56038A (fr) 2022-04-06
KR20220027871A (ko) 2022-03-08
JOP20210318A1 (ar) 2023-01-30
ECSP21093623A (es) 2022-01-31
US20230080834A1 (en) 2023-03-16
EP3976597A1 (en) 2022-04-06
PE20220768A1 (es) 2022-05-16
JP2022534302A (ja) 2022-07-28
US20210300918A1 (en) 2021-09-30
DOP2021000244A (es) 2022-04-18
CR20210587A (es) 2022-02-11
SG11202112994WA (en) 2021-12-30
MX2021014679A (es) 2022-04-06
US11254673B2 (en) 2022-02-22
WO2020239999A1 (en) 2020-12-03
IL288387A (en) 2022-01-01
BR112021023796A2 (pt) 2022-02-08
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
CA3143350A1 (en) 2020-12-03
CO2021017838A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
CL2021003142A1 (es) Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb.
CO2022010241A2 (es) Inhibidores de sos1
ECSP15042895A (es) Compuestos de biaril-amida como inhibidores de cinasa
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CU20130033A7 (es) Imidazopiridazinas sustituidas
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CU20170029A7 (es) Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CL2016001409A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
BR112017008045A2 (pt) compostos como inibidores de nik
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
UY35823A (es) Profármacos de antagonista de nmda
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor